The ESD discharge monitoring system

Występowanie wyładowań elektrostatycznych prowadzi do powstawania bardzo dużych strat w produkcji lub serwisie w przypadku jego uszkodzenia. W niektórych przypadkach konieczne jest monitorowanie jego występowania w strefie (obszarze) chronionej. W artykule przedstawiono prowadzone prace nad systemem wykrywania wyładowań elektrostatycznych opartym o odbiór i analizę sygnału emisji elektromagnetycznej powstającego w momencie jego wystąpienia. Przedstawiono uzyskane wyniki z badań oraz zrealizowany na ich podstawie układ detekcji wykrywania wyładowań elektrostatycznych.The occurrence of electrostatic discharge can lead to very large losses in production or service of electronic equipment. In case of special production ESD can even lead to serious accidents. Phenomenon of electrostatic discharge (ESD) is related to such physicochemical processes like friction, grinding, spraying and rapid separation or combining of non-conductive, or well-insulated solid, liquid and/or gas. In some cases it is necessary to monitor continuously the protected zone. This article presents ongoing work on electrostatic discharge detection system based on the collection and analysis of electromagnetic emission signal appearing at the time of ESD occurrence. The paper presents the results of research and realized on the basis of them electrostatic discharge detection system

Removal of hydrophobic organic pollutants from soil by washing using solutions of mixtures of sugar and gemini surfactants

Zbadano wpływ surfaktantów gemini w mieszaninach z alkilopoligluko-zydami na odmywanie heksadekanu z gleby. Dodatek surfaktantu gemini powodował wzrost usunięcia heksadekanu z gleby torfowej w stosunku do roztworów czystego Tritonu BG10. Największy wzrost efektywności uzyskano stosując hydrofilowe surfaktanty gemini Surfynole S465 i S485 w stężeniu 0,5 g/dnrl W przypadku gleby piaszczystej nie stwierdzono poprawy usunięcia heksadekanu w wyniku dodania surfaktantów gemini.The influence of different gemini surfactants in mixtures with alkylpolyglu-cosides - Triton BG10 on removal of hexadecane from soil was investigated. Addition of gemini surfactant resulted in improve hexadecane removal from peat soil. Best results were obtained using hydrophilic gemini surfactants Surfynol S465 and S485 at concentration of 0.5 g/dm3. In the case of sandy soil there was no improvement in removal of hexadccane by the addition of gemini surfactants

Application of non-ionic surfactants in removal of chloroorganic contaminants from soil

Zbadano solubilizację micelarną tetrachloroetylenu w roztworach al-kilopoliglukozydów (Triton BG10 i AG (>210). Przeprowadzono procesy przemywania gleby zanieczyszczonej tetrachloroetylenera przy użyciu roztworów alkilopoliglukozydów oraz oksyetylenowanych alkoholi (Rokanole NL5, NL6, NL8, L7, L10). Określono wpływ hydrofilowości surfaktantu i jego stężenia na efektywność przemywania gleby.Micellar solubilization of tetrachloroethylene in solutions of alkylpoly-glucosides (Triton BG10, AC 6210) and ability of alkylpolyglucosides and polyethoxylated alcohols (Rokaiiol NL5, NL6, NL8, L7, L10) for removal of tetrachloroethylene from soil were investigated. Influence of hydrophilicity of surfactants and their concentration in solution on washing efficiency was investigated

Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine ▿

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an increasingly common cause of health care-associated urinary tract infections. Antimicrobials with in vitro activity against CRKP are typically limited to polymyxins, tigecycline, and often, aminoglycosides. We conducted a retrospective cohort study of cases of CRKP bacteriuria at New York-Presbyterian Hospital from January 2005 through June 2010 to compare microbiologic clearance rates based on the use of polymyxin B, tigecycline, or an aminoglycoside. We constructed three active antimicrobial cohorts based on the active agent used and an untreated cohort of cases that did not receive antimicrobial therapy with Gram-negative activity. Microbiologic clearance was defined as having a follow-up urine culture that did not yield CRKP. Cases without an appropriate follow-up culture or that received multiple active agents or less than 3 days of the active agent were excluded. Eighty-seven cases were included in the active antimicrobial cohorts, and 69 were included in the untreated cohort. The microbiologic clearance rate was 88% in the aminoglycoside cohort (n = 41), compared to 64% in the polymyxin B (P = 0.02; n = 25), 43% in the tigecycline (P < 0.001; n = 21), and 36% in the untreated (P < 0.001; n = 69) cohorts. Using multivariate analysis, the odds of clearance were lower for the polymyxin B (odds ratio [OR], 0.10; P = 0.003), tigecycline (OR, 0.08; P = 0.001), and untreated (OR, 0.14; P = 0.003) cohorts than for the aminoglycoside cohort. Treatment with an aminoglycoside, when active in vitro, was associated with a significantly higher rate of microbiologic clearance of CRKP bacteriuria than treatment with either polymyxin B or tigecycline

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 ARDS. The objective of this study was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC-MSC) infusions in subjects with COVID-19 ARDS. A double-blind, phase 1/2a, randomized, controlled trial was performed. Randomization and stratification by ARDS severity was used to foster balance among groups. All subjects were analyzed under intention to treat design. Twenty-four subjects were randomized 1:1 to either UC-MSC treatment (n = 12) or the control group (n = 12). Subjects in the UC-MSC treatment group received two intravenous infusions (at day 0 and 3) of 100 ± 20 × 10 UC-MSCs; controls received two infusions of vehicle solution. Both groups received best standard of care. Primary endpoint was safety (adverse events [AEs]) within 6 hours; cardiac arrest or death within 24 hours postinfusion). Secondary endpoints included patient survival at 31 days after the first infusion and time to recovery. No difference was observed between groups in infusion-associated AEs. No serious adverse events (SAEs) were observed related to UC-MSC infusions. UC-MSC infusions in COVID-19 ARDS were found to be safe. Inflammatory cytokines were significantly decreased in UC-MSC-treated subjects at day 6. Treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). UC-MSC infusions are safe and could be beneficial in treating subjects with COVID-19 ARDS